Previous Close | 0.4000 |
Open | 0.5000 |
Bid | 0.4500 |
Ask | 0.7500 |
Strike | 6.00 |
Expire Date | 2025-01-17 |
Day's Range | 0.5000 - 1.3000 |
Contract Range | N/A |
Volume | |
Open Interest | 102 |
SEATTLE, June 03, 2024--Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending the maturity profile on a substantial portion of its debt from February 2026 to June 2028, while providing a secure source of capital to support potential commercialization of its lectin pathway inhibitor narsoplimab and flexibility to manage the remaining balance of 2026 convertible notes.
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.